Skip to content

CRESCENT BIOPHARMA, INC.: 10-K filed 2020-02-28

What CRESCENT BIOPHARMA, INC. reported in its annual report filed 2020-02-28 (fiscal FY 2019): 34 published measures, 91 facts as tagged in accession 0001558370-20-001723.

This filing

Form
10-K (annual report)
Filed
2020-02-28
Fiscal period
fiscal FY 2019
Accession
0001558370-20-001723 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CRESCENT BIOPHARMA, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2019-12-31167,969,679USD
At 2018-12-31214,839,272USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2019-12-3113,769,092USD
At 2018-12-319,374,777USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2019-12-31154,200,587USD
At 2018-12-31205,464,495USD
At 2017-12-31119,701,425USD
At 2016-12-3135,301,131USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2019-12-31158,201,441USD
At 2018-12-31209,917,595USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2019-10-01 to 2019-12-31-14,726,317USD92
2019-01-01 to 2019-12-31-57,891,911USD365
2019-07-01 to 2019-09-30-13,251,882USD92
2019-04-01 to 2019-06-30-15,829,815USD91
2019-01-01 to 2019-03-31-14,083,897USD90
2018-10-01 to 2018-12-31-13,906,915USD92
2018-01-01 to 2018-12-31-48,273,633USD365
2018-07-01 to 2018-09-30-11,575,111USD92
2018-04-01 to 2018-06-30-11,278,763USD91
2018-01-01 to 2018-03-31-11,512,844USD90
2017-01-01 to 2017-12-31-33,281,068USD365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2019-01-01 to 2019-12-31-51,984,139USD365
2018-01-01 to 2018-12-31-43,331,130USD365
2017-01-01 to 2017-12-31-29,768,361USD365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2019-01-01 to 2019-12-31144,928USD365
2018-01-01 to 2018-12-31125,618USD365
2017-01-01 to 2017-12-31294,107USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2019-01-01 to 2019-12-31412,913USD365
2018-01-01 to 2018-12-31129,449,605USD365
2017-01-01 to 2017-12-31113,945,565USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2019-01-01 to 2019-12-31-144,928USD365
2018-01-01 to 2018-12-31-125,618USD365
2017-01-01 to 2017-12-31-294,107USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2019-12-31-258,442,650USD
At 2018-12-31-200,550,739USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2019-12-31822,920USD
At 2018-12-31957,226USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2019-01-01 to 2019-12-316,215,090USD365
2018-01-01 to 2018-12-314,587,098USD365
2017-01-01 to 2017-12-313,760,802USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2019-01-01 to 2019-12-31-61,389,302USD365
2018-01-01 to 2018-12-31-51,504,823USD365
2017-01-01 to 2017-12-31-33,932,280USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2019-12-31162,527,763USD
At 2018-12-31212,269,119USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2019-12-3110,950,576USD
At 2018-12-318,763,154USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2019-12-311,435,660USD
At 2018-12-312,663,579USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2019-01-01 to 2019-12-3161,389,302USD365
2018-01-01 to 2018-12-3151,504,823USD365
2017-01-01 to 2017-12-3133,932,280USD365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2019-01-01 to 2019-12-3147,029,264USD365
2018-01-01 to 2018-12-3140,091,773USD365
2017-01-01 to 2017-12-3124,100,092USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2019-12-3143,466,933shares
At 2018-12-3143,160,751shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2019-12-31158,201,441USD
At 2018-12-31209,917,595USD
At 2017-12-31123,924,738USD
At 2016-12-3140,041,641USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2019-12-31412,599,772USD
At 2018-12-31405,972,075USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2019-12-313,006,069USD
At 2019-01-013,600,000USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2019-12-313,622,642USD
At 2019-01-014,300,000USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2019-12-312,684,465USD
At 2018-12-312,540,868USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2019-12-311,861,545USD
At 2018-12-311,583,642USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2019-12-318,710,790USD
At 2018-12-316,000,804USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2019-12-314,326,322USD
At 2018-12-312,351,524USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2019-12-31971,278USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2019-01-01 to 2019-12-31-57,891,911USD365
2018-01-01 to 2018-12-31-48,273,633USD365
2017-01-01 to 2017-12-31-33,281,068USD365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2019-01-01 to 2019-12-3114,360,038USD365
2018-01-01 to 2018-12-3111,413,050USD365
2017-01-01 to 2017-12-319,832,188USD365

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2019-01-01 to 2019-12-31279,234USD365
2018-01-01 to 2018-12-31275,123USD365
2017-01-01 to 2017-12-31263,541USD365

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2018-01-01 to 2018-12-31128,425,080USD365
2017-01-01 to 2017-12-31113,572,189USD365

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

PeriodValueUnitDays
2019-01-01 to 2019-12-31941,089USD365

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2019-01-01 to 2019-12-31-1,227,919USD365
2018-01-01 to 2018-12-3116,488USD365
2017-01-01 to 2017-12-311,061,880USD365

Inspect the source

Entity
CRESCENT BIOPHARMA, INC. / CIK 0001253689
Captured
2026-09-20T07:46:49.806Z
SEC response SHA-256
b4a6cd55809d9037713a6469afddaa482d358690abc0227f51b6714b6bda1dce

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001253689.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))